NEW YORK – Dario Amodei, CEO of artificial intelligence developer Anthropic, publicly committed to resisting business and political pressures to compromise on AI safety, even as the company made a monumental debut on the Nasdaq exchange. On November 19, under the ticker "ANT," the five-year-old creator of the Claude AI models achieved a fully diluted market capitalization of approximately $1.8 trillion.
Amodei's remarks accompanied Anthropic's record-breaking initial public offering, which saw the company raise $81.3 billion. This surpassed SpaceX's previous record, as Anthropic sold 980 million shares at $83 apiece. Shares opened at $111.50 and closed up 17% at $97.17, with over 846 million shares traded.
Prioritizing Safety Amidst Rapid Growth
Despite public investors driving a 1,200% revenue surge, with Anthropic reporting $33.24 billion in revenue for the nine months ending September 30, Amodei maintained his focus on the profound societal and existential implications of machine intelligence. He stated unequivocally, "We will pace the training and deployment of AI systems, taking as long as is necessary to have confidence that they are safe and will remain under human control. We will not bend to either business or political pressure."
Amodei warned of severe hazards associated with AI, including potential misuse by individuals or nation-states, economic disruption, and the loss of system control. He emphasized that avoiding these risks hinges entirely on deliberate choices made by developers. "There is much work still to be done, and the most difficult safety work lies ahead of us," he added, stressing the need for rigorous double and triple-checking of AI systems for safety and security.
A Vision for Scientific and Economic Advancement
Tracing Anthropic’s founding mission, Amodei shared a personal connection to scientific progress, noting his father's passing from a disease that later became curable. He highlighted how researchers are already leveraging Claude for tasks like protein folding, drug design, cancer genetics, and clinical trial administration, significantly compressing research timelines.
"I believe sufficiently powerful AI, working in concert with humans, could compress a century of scientific and medical progress into a decade," Amodei projected, though he cautioned that current results are early. Beyond medicine, Anthropic's models are being applied to stimulate economic growth, protect democratic institutions, and streamline everyday services. Amodei hopes that Anthropic's commercial success, coupled with its safety-first approach, will inspire an industry-wide "race to the top" in safe AI development.
"The advent of machine intelligence is one of the seminal moments in human history, and we have a rare opportunity to shape it for the better," Amodei concluded. "This moment is bigger than any one company, or any one country. It will take all of us, working together, to ensure this technology goes well for us and the many generations to come."